OS Therapies Inc
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 |
|---|---|---|---|---|
| Income Statement | ||||
| Research and development | $16.4M | $2.8M | $3.2M | — |
| Operating income | -$28.7M | -$6.8M | -$4.3M | — |
| Interest expense | — | $2.1M | $3.4M | — |
| Net income | -$28.8M | -$8.9M | -$7.8M | — |
| Balance Sheet | ||||
| Current assets | $332,912 | $5.5M | $790,032 | — |
| Total assets | $6.8M | $5.5M | $798,082 | — |
| Current liabilities | $11.8M | $4.6M | $24.7M | — |
| Total liabilities | $11.9M | $4.7M | $24.8M | — |
| Stockholders' equity | -$6.1M | -$3.3M | -$24.0M | -$17.6M |
| Cash Flow Statement | ||||
| Cash from operations | -$14.2M | -$7.3M | -$3.0M | — |
| Depreciation and amortization | $363,085 | $2,780 | $4,220 | — |
| Stock-based compensation | $4.3M | $268,300 | $0 | — |
| Capital expenditure | $466,423 | — | — | — |
| Free cash flow | -$14.7M | — | — | — |
Shares outstanding 44.5M · Free float 86.7%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.